Fred Hutchinson Cancer Research Center biostatistician Dr. James Dairecently was awarded a $2.1 million grant from the National Cancer Institute to develop new analytical methods for identifying genetic and epigenetic alterations that drive cancers. He hopes this work will facilitate the discovery of molecular cancer drivers — biomarkers — and the development of new preventive, diagnostic and prognostic techniques.
Dai is using data from prostate cancer studies conducted by Fred Hutch epidemiologist Dr. Janet Stanford and SWOG biostatistician Dr. Catherine Tangen that measure how genetics, epigenetics, and environment and lifestyle factors can influence the risk and prognosis ofdisease. Dai hopes to assess the clinical implications of these alterations while developing statistical methods for monitoring:
